Previous Article | Next Article ![]()
Journal of Virology, May 2006, p. 4921-4926, Vol. 80, No. 10
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.10.4921-4926.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Departments of Neurology,1 Microbiology, University of Colorado Health Sciences Center, Denver, Colorado 802622
Received 19 January 2006/ Accepted 27 February 2006
|
|
|---|
|
|
|---|
To date, sequence analysis has verified the transcription of 5 of the approximately 70 known VZV open reading frames (ORFs 21, 29, 62, 63, and 66) in latently infected human ganglia (4, 5). Nevertheless, the mechanism by which these five genes are regulated during latency is unknown. Analyses of other human herpesviruses have revealed that virus gene regulation is associated with chromatin. Promoter regions regulating both Epstein-Barr virus (EBV) and herpes simplex virus type 1 (HSV-1) latently transcribed genes are associated with posttranslationally modified histone proteins, indicative of a euchromatic, transcriptionally permissive state (16, 18, 19, 27).
The basic unit of chromatin is the nucleosome, which is composed of a histone protein core entwined with a coil of DNA. Gene transcription, replication, and DNA repair result from modifications of histone core proteins, usually by methylation, phosphorylation, and acetylation (25, 30). For example, acetylation at histone protein H3 residues lysine 9 and lysine 14 in the histone core results in a euchromatic configuration of nucleosomes (12, 29). To determine whether VZV DNA is associated with chromatin in latently infected human ganglia, we studied four virus genes, two of which (VZV genes 62 and 63) are frequently transcribed in latently infected human ganglia (4, 6, 14) and two of which (VZV genes 36 and 14) are not transcribed during latency (11). A chromatin immunoprecipitation (ChIP) assay was used to determine the association of the histone protein H3 modified by acetylation at lysine 9 [H3K9(Ac)] with the promoters regulating VZV gene 14, 36, 62, and 63 transcription in latently infected ganglia compared to that in cells in tissue culture productively infected with VZV.
|
|
|---|
Preparation of VZV-infected MeWo cells. VZV-infected MeWo cells in 100-mm2 dishes were washed at 3 days postinfection with 1.0 ml of ice-cold phosphate-buffered saline (PBS) containing protease inhibitors (1x Complete Mini, used according to the manufacturer's instructions; Roche, Penzberg, Germany) (PBS-PI). After the removal of PBS-PI and the addition of 1.0 ml of fresh PBS-PI, cells were scraped into 15-ml conical tubes and brought to a final volume of 2.0 ml. DNA-protein complexes were cross-linked by the addition of 43.2 µl formaldehyde, vortexed for 10 s, and rocked horizontally on an orbital shaker for 10 min at room temperature. Glycine was added to a final concentration of 0.128 M, followed by vortexing and rocking on an orbital shaker for 5 min at room temperature. After centrifugation at 5,000 rpm for 5 min at 4°C, the cell pellet was washed and resuspended in 1 ml PBS-PI by vortexing. The pellet was recentrifuged at 5,000 rpm at 4°C for 5 min, washed once in PBS-PI, resuspended in 500 µl of sodium dodecyl sulfate lysis buffer (Upstate Biotech, Charlottesville, Va.), and incubated for 10 min on ice. Lysates were transferred to sterile 5-ml polypropylene culture tubes, brought to 1 ml with ChIP dilution buffer (Upstate), and placed in an ice-salt slurry at 7°C. Samples were sonicated (Sonifer W140D cell disruptor; Heat Systems-Ultrasonics, Farmingdale, NY) three times for 30 s each time at a setting of 3, with 90-s cooling intervals.
Preparation of human tissue. Trigeminal ganglia (TG) were removed within 24 h of death from the subjects listed in Table 1. No subject had any signs of recent herpesvirus reactivation, and the patients were not immunocompromised before death. Each TG was washed twice in modified Eagle's medium and ground separately with a mortar and pestle in 750 µl of ice-cold PBS-PI. The homogenate was removed and, after the addition of 750 µl of ice-cold PBS-PI to the remaining tissue, further homogenized. Both 750-µl homogenates were combined, followed by the addition of 430 µl PBS-PI and 43.2 µl formaldehyde to yield a final concentration of 0.6% formaldehyde. The samples were vortexed for 10 s and rocked on an orbital shaker for 10 min at room temperature. The remaining preparation procedures were identical to those described above for MeWo cells.
|
View this table: [in a new window] |
TABLE 1. Clinical information for subjects in this study
|
Chromatin preclearing. After confirmation of chromatin size, the left and right TG samples were combined and centrifuged at 13,000 rpm at 4°C for 10 min. The supernatant was collected, diluted 1:10 with ChIP dilution buffer (Upstate), and incubated with a 50% (wt/vol) salmon sperm DNA-protein A agarose slurry (Upstate) (240 µl per TG pair) for 2 h at 4°C with shaking. Samples were centrifuged, and the supernatant was divided into 950-µl fractions.
Chromatin immunoprecipitation. TG or cell samples were incubated with antibodies (3 µl) directed against the H3K9(Ac) protein (Upstate) or with control human immunoglobulin G (IgG; Vector, Burlingame, CA) overnight at 4°C with shaking in the dark. After further inoculation with a 50% (wt/vol) salmon sperm DNA-protein A agarose slurry (30 µl) at 4°C for 90 min with shaking, the antibody complexes were pelleted at 7,000 rpm for 30 s.
Supernatants (300 µl) from the human IgG controls were removed (unbound fractions). The pellets precipitated with H3 antibody (bound fractions) were washed according to the manufacturer's instructions (ChIP assay kit; Upstate Biotech), and the complexes were eluted from beads with preheated (65°C) elution buffer (0.1% sodium dodecyl sulfate, 0.1 M NaHCO3). Cross-linking was reversed by incubation with NaCl (final concentration, 0.2 M) for 4 h at 65°C. Samples were also treated with RNase (40 µg/ml) for 30 min at 37°C. Protein in the sample was degraded by incubation with EDTA (final concentration, 0.01 M), Tris, pH 6.5 (final concentration, 0.02 M), and proteinase K (40 µg/ml) at 65°C for 4 h.
PCR. DNA was purified using a QIAquick PCR purification kit (QIAGEN, Germany). Equivalent volumes of the bound and unbound fractions were analyzed by PCR. Figure 1 shows the complete 125-kbp VZV genome and identifies the positions of VZV ORFs 14, 36, 62, and 63. Both a putative early gene (ORF 36) that encodes thymidine kinase and a late gene (ORF 14) encoding glycoprotein C were chosen. The promoter regions for the selected ORFs studied herein are also shown (Fig. 1D and E). Table 2 lists the sequences of VZV and cell primers used. For PCR, samples were initially incubated for 1 min at 95°C, followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72 for 1 min, with a final cycle of 94°C for 30 s, 55°C for 30 s, and 72°C for 7 min. The amplified material was resolved in 8.0% acrylamide gels, visualized with SYBR green at a concentration recommended by the supplier's (Invitrogen) instructions, and imaged on a Storm imager (Molecular Dynamics, Fairfield, Conn.).
![]() View larger version (11K): [in a new window] |
FIG. 1. Schematic representation of VZV genome and locations of oligonucleotide primers. (A) The VZV genome consists of unique long (UL) and unique short (US) segments, each bracketed by repeat sequences. The UL is bracketed by terminal repeat (TRL) and internal repeat (IRL) sequences; US is also bracketed by terminal repeat sequences (TRS) and internal repeat sequences (TRS/IRS). (B) ORFs 14 and 36 are located within the UL and are transcribed in opposite directions. ORFs 62 and 63 map within IRS and also within TRS (ORFs 70 and 71, respectively). (C) Details of the VZV ORFs showing the locations of the ORF start sites and the origin of DNA replication (ori) between ORFs 62 and 63. (D) Further details of VZV ORFs 14, 36, 62, and 63, including TATA sites, minor transcriptional start sites, poly(A) sequences, and locations of untranslated regions (UTR). The major transcriptional start site of each ORF is referenced as +1. (E) Locations of oligonucleotide primers.
|
|
View this table: [in a new window] |
TABLE 2. PCR primers used in this study
|
|
|
|---|
![]() View larger version (60K): [in a new window] |
FIG. 2. Sensitivities of PCR primers. (A) NHB DNA was extracted, quantitated, diluted from 3 x 104 to 3 x 100 cell genome equivalents (based on the presence of 3 x 109 bp in one cell), and amplified with PCR primers specific for GAPDH (primer set 5/6) or the chromosome 4 centromere. Both cellular control PCR primer sets detected 30 genome equivalents of NHB DNA. (B) DNA was extracted from isolated VZV nucleocapsids, quantitated, diluted (105 to 101 virus DNA copies), and amplified with primers specific for VZV ORFs 62, 63, 36, and 14. A VZV-specific PCR product (103 copies) was detected with every primer set.
|
![]() View larger version (33K): [in a new window] |
FIG. 3. ChIP assay of VZV-infected MeWo cells (2 x107) harvested 3 days after infection. (A) DNA within the immunocomplex formed by antibody directed against H3K9(Ac) was extracted and PCR amplified in duplicate with cell control- and VZV-specific primer sets. Centromere-specific primers did not yield a detectable product (<103 cell genome equivalents). The GAPDH (primer set 1/2) and VZV-specific primer sets yielded PCR products. (B) DNA was extracted from supernatants of samples immunoprecipitated with a human anti-IgG control antibody. All six targets were amplified when unbound DNA was used as the PCR template.
|
![]() View larger version (40K): [in a new window] |
FIG. 4. ChIP assay of latently infected human trigeminal ganglia. Both trigeminal ganglia were removed from three subjects at autopsy and processed for ChIP analysis as described in Materials and Methods. (A) DNA contained within the immunocomplex formed by antibody directed against H3K9(Ac) was extracted and PCR amplified in duplicate with cell control- and VZV-specific primer sets. Centromere-specific primers and primers specific for VZV ORFs 36 and 14 did not yield detectable products (<103 cell genome equivalents and <103 VZV DNA copies, respectively). GAPDH primer set 5/6 and primers specific for VZV ORFs 62 and 63 yielded PCR products. (B) DNA was extracted from the supernatants of samples immunoprecipitated with a human anti-IgG control antibody. All six targets were amplified when this unbound DNA was used as the PCR template.
|
|
|
|---|
In VZV-infected MeWo cells, the promoters for ORFs 14, 36, 62, and 63 were associated with histone H3K9(Ac), in accord with the previous detection of these transcripts in diverse productively infected cells (6, 13, 15, 17, 24). In HSV-1-infected cells in tissue culture, virus genes of all three kinetic classes (immediate-early, early, and late) were associated with H3K9(Ac) as well as with H3K14(Ac) (16).
Epigenetic regulation of virus gene transcription through chromatin structure has also been demonstrated for cells productively and latently infected with EBV. Specifically, in type I latently infected B cells, the promoters regulating EBNA-2 and LMP-1 transcription are associated with acetylated and methylated H3 and H4 proteins, resulting in transcriptional repression (1, 9, 10, 21, 22, 26, 27). Demethylation of the EBNA-2 and LMP-1 promoters activates transcription and mediates a switch from type I to type III EBV latency (1, 30).
Our results demonstrate that in ganglia latently infected with VZV, promoter regions regulating the transcription of two latently expressed VZV genes are associated with H3K9(Ac). Conversely, the promoters regulating the transcription of two VZV genes expressed solely during productive infection were not associated with H3K9(Ac). Therefore, the promoters for VZV genes 14 and 36 may be associated with a form of the H3 protein that leads to repression of gene transcription. Such an H3 modification is methylation at lysine 9 [H3K9(Me)] (20). We are currently investigating the association of H3K9(Me) with VZV ORF 14 and 36 promoter regions by a quantitative ChIP analysis that incorporates real-time PCR analysis of immunoprecipitated DNA. Associations of the VZV gene 14 and 36 promoters with H3K9(Me) would maintain those DNA regions in a heterochromatic state and keep them inaccessible for transactivation by VZV IE62. VZV IE62 is required for activation of the VZV gene 14 and 36 promoters (13). Removal of the methyl group on H3K9 by cellular demethylase, followed by K9 acetylation, has been shown to initiate a transition from type I to type III latency in EBV (1, 30). Thus, histone H3 modification, methylation, or acetylation may be a key regulator in the transcription of alphaherpesvirus genes leading to the establishment and maintenance of virus latency in human ganglia. Supporting this notion are recent reports comparing histone H3 modifications on HSV-1 gene promoters during latent infection and after virus reactivation in mouse models (2, 28). A greater association of heterochromatic H3K9(Me) with HSV-1 lytic gene promoters was found during latency than during virus reactivation. In addition, the HSV-1 LAT promoter and 5' exon/enhancer region were shown to undergo a transition from euchromatic to heterochromatic H3 modification concomitant with an increase in euchromatic H3K9 hyperacetylation of the HSV-1 ICP4 promoter during reactivation. Taken together, these findings suggest that the HSV-1 LAT locus, associated with euchromatic H3K9(Ac) and H3K4(Me), is actively transcribed and functions, in part, to maintain the HSV-1 ICP4 promoter in a heterochromatic H3K9(Me) state. Upon reactivation, the LAT promoter/enhancer becomes progressively heterochromatic, whereas the HSV-1 ICP4 promoter becomes progressively euchromatic. Interestingly, VZV lacks a definable LAT locus, and VZV ORF 62 transcripts have been detected in latently infected human ganglia (4). Thus, a basic difference in the transcriptional patterns of HSV-1 ICP4 and VZV ORF 62 during latency is the posttranslational modification of histone protein H3, controlled in part by LAT, a gene present in HSV-1 but not found in VZV.
In summary, our study describes the first detection of a modified histone H3 protein associated with promoters for VZV genes that are transcribed in latently infected human ganglia and provides a rationale for further study of epigenetic gene regulation by alphaherpesviruses during latent infection.
We thank Mark Burgoon for the anti-human IgG antibody, Marina Hoffman for editorial assistance, and Cathy Allen for manuscript preparation.
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»